Meeting
2019 Gastrointestinal Cancers Symposium
Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in first line metastatic pancreatic cancer (MPC): Updated results.
Authors
Vincent J. Picozzi
Virginia Mason Hospital and Medical Center, Seattle, WA
Vincent J. Picozzi , Bruce Shih-Li Lin , Margaret T. Mandelson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 314)
DOI
10.1200/JCO.2019.37.4_suppl.314
Abstract #
314
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder
Poster
2019 Gastrointestinal Cancers Symposium
Sequential gemcitabine (G), oxaliplatin (O), and irinotecan (I) based weekly metronomic chemotherapy (MC) regimens for the treatment of metastatic pancreatic cancer (mPC): A community cancer clinic experience.
First Author: Ben M. Chue
Poster
2018 Gastrointestinal Cancers Symposium
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
First Author: Elisa Giommoni
Poster
2014 ASCO Annual Meeting
Patterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts) with metastatic pancreatic cancer (MPC).
First Author: Thomas Adam Abrams